The cold wave has exceeded the standard by a large margin!

On the morning of November 22, some southern friends in the author’s circle of friends, including Jinhua and Huangshan, updated the news about snow.
Even though the author was in sunny Hangzhou, he obviously felt the chill of the temperature drop
.
According to the China Meteorological Observatory, China has ushered in the third nationwide cold wave since October, far exceeding normal data
.
However, in the case of the cold wave greatly exceeding the standard, the biological medicine equipment industry has shown a fiery scene
.
Policies, capital, talents, etc.
support the innovation and upgrading of the biomedical industry.
According to the definition, biomedicine refers to the use of research results in microbiology, biology, medicine, biochemistry, etc.
, from organisms, biological tissues, cells, body fluids, etc.
, A class of products used for prevention, treatment and diagnosis, manufactured by comprehensively utilizing a variety of scientific principles and methods
.
Compared with chemical drugs, biological drugs have higher technical barriers, more complex production processes, and very high R&D costs involved
.
In recent years, under the influence of multiple factors such as continuous increase in policies, capital entry, and the influx of talents, China's biomedical industry has developed rapidly and accelerated the pace of innovation and upgrading.
Innovative biopharmaceuticals such as double antibodies, ADC, CAR-T and other products Constantly emerging in the domestic market, the targets involved are gradually diversified
.
Data show that China’s biopharmaceutical industry is currently maintaining a rapid development trend, and the overall market scale is constantly expanding.
The market size in 2016 was 183.
6 billion yuan, and it has grown to 345.
7 billion yuan by 2020.
The market is expected to continue to grow in the future.
It is expected to continue to grow in 2021.
It will reach 424.
8 billion yuan in the year
.
According to Frost & Sullivan’s report, China’s biopharmaceutical market will exceed US$100 billion in 2024
.
The upstream equipment industry is also showing a hot scene.
Related companies are actively deploying Biopharmaceutical equipment is an industry upstream of the biopharmaceutical industry.
In the context of the rapid development of the biopharmaceutical industry, the related equipment industry also shows a hot scene
.
Judging from the 2021 three-quarter reports of major pharmaceutical machinery companies, some companies have already tasted the "big sweetness" in the face of strong demand for biopharmaceutical equipment
.
For example, the third quarter report of Chutian Technology for 2021 shows that the net profit of the first three quarters increased by more than 723% year-on-year.
The reason is that there are sufficient orders for biopharmaceutical equipment.
It is expected to maintain high growth in the fourth quarter and subsequent quarters; Xinlai Yingcai benefited from Domestic vaccine and pharmaceutical manufacturers have rapidly expanded their production, and the company's biomedical business has grown rapidly in the first three quarters.
The company's net profit attributable to its parent from January to September increased by 92% year-on-year
.
Facing the development opportunities of the biopharmaceutical equipment industry, many equipment manufacturers are actively deploying
.
For example, Chutian Technology disclosed in its research activity information published on September 15 this year that it will take heavy investment and major development in biopharmaceutical-related products, and plan to increase the sales growth rate of process technology and process equipment related to biopharmaceuticals every year.
Other product lines are benchmarking Sartorius in the biological field to complement related product series and industrial chains
.
In August and September this year, Chutian Technology has successively established holding subsidiaries, Chutian Siyoute and Chutian Microsphere, to further supplement the biopharmaceutical-related equipment and product chain
.
For another example, Tofflon had previously revealed in its previous surveys that the preparation of biomedicine's original solution and the output of engineering capabilities are the track for the rapid growth of the demand for innovative drugs in China and even the global market in the future.
The company plans to form a team to meet the domestic and foreign markets.
Demand
.
In addition, Canaan Technology has also stated that the company plans to focus on the development of pharmaceutical liquid dispensing systems, intelligent logistics systems and pharmaceutical R&D services for bio-innovative drugs.
It believes that the rapid development of the biopharmaceutical industry will bring more business opportunities to the company
.
Conclusion Although the cold wave hits, the biopharmaceutical equipment industry presents a fiery scene
.
While seizing opportunities, relevant companies also need to pay attention to market trends and actual needs of users
.
For example, compared with traditional stainless steel reactors, disposable reactors can improve production efficiency, ensure product quality, and solve the pain of enterprise cost.
It is expected that the disposable bioreactor market will usher in rapid growth in the future, while traditional stainless steel reactors Tanks and other equipment will be eliminated
.
However, the current disposable bioreactors in the domestic market are still dominated by foreign giants.
Under this background, domestic enterprises still need to continue to make efforts to accelerate the realization of domestic substitution by increasing innovation and research and development
.